Observational studyBMC cardiovascular disorders2026
Effect of coded steatotic liver disease on outcomes of percutaneous coronary intervention in non-diabetic adults: insights from a multicenter real-world cohort.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a cardiovascular risk-enhancing condition. Its prognostic significance following PCI in non-diabetic adults, and the temporal distribution of that risk, remain incompletely characterized.
objectivesTo evaluate whether coded steatotic liver disease is associated with adverse one-year post-PCI outcomes in non-diabetic adults, and to characterize the temporal concentration of risk across early (day 0-30) and late (day 31-365) post-procedural periods.
methodsRetrospective cohort study using the TriNetX US Collaborative Network (2014-2023). Non-diabetic adults undergoing PCI were stratified by steatotic liver disease (SLD) status (ICD-10-CM K76.0 and/or K75.81). PRIMARY OUTCOME: all-cause mortality (day 1-365). SECONDARY OUTCOMES: heart failure, MI, 3-point MACE, cardiogenic shock, cardiac arrest, and bleeding. PSM (1:1) balanced demographics, cardiometabolic comorbidities, ACS type, and medications. Outcomes were further assessed across prespecified early and late windows.
resultsAfter PSM, 7,434 patients per group were well balanced (SMD < 0.10). All-cause mortality did not differ significantly (2.8% vs. 3.1%; HR, 0.93; 95% CI, 0.77-1.13; p = 0.472). SLD was significantly associated with higher one-year rates of incident heart failure (10.1% vs. 8.9%; HR, 1.15; 95% CI, 1.02-1.30; p = 0.027) and bleeding events (5.1% vs. 3.8%; HR, 1.35; 95% CI, 1.15-1.59; p < 0.001). Time-stratified analysis showed that cardiogenic shock risk was concentrated in the first 30 days (RR, 1.45; p < 0.001) and attenuated to null beyond 30 days and overall. Heart failure excess was similarly early-driven (RR, 1.17; p = 0.005), but the overall one-year signal remained significant (HR, 1.15; p = 0.027), reflecting the sustained contribution of early events.
conclusionsAmong non-diabetic adults undergoing PCI, coded steatotic liver disease is associated with significantly higher one-year rates of heart failure and bleeding, without a significant mortality difference. Hemodynamic vulnerability is concentrated in the early peri-procedural period, while hemorrhagic risk is sustained. These findings support heightened early surveillance and individualized antithrombotic planning for SLD patients undergoing PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.